

USA PATENT GRANTED FOR GAME-CHANGING NET TECHNOLOGY FOR EXOSOME CAPTURE

- **US Patent granted for BARD1's Molecular Net biomarker capture technology**
- **Provides patent protection for the technology, including exosome-specific EXO-NET™, in USA until 2031**
- **Supports the planned launch of RUO EXO-NET product in the US in 2021 and entry into the US\$2.3b global diagnostic and therapeutic exosomes market¹**

Melbourne, Australia, 28 January 2021: BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or the **Company**) is pleased to announce that it has been granted US patent number 10,900,962 entitled 'Molecular nets and devices for capturing analytes including exosomes' by the United States Patent and Trademark Office (USPTO) on 26 January 2021. The patent family was filed on 6 July 2017 and is owned by Sienna Cancer Diagnostics Inc, a wholly owned subsidiary of BARD1 Life Sciences Ltd. US patent 10,900,962 will expire on 19 August 2031.

This patent covers BARD1's unique **Molecular Net** technology. Molecular Nets are multilayered three-dimensional matrices comprising capture molecules, linkers and spacers that can be custom built for rapid, specific, and sensitive analyte capture from a biological sample. It also includes one specific type of Molecular Net, BARD1's antibody-based EXO-NET™, designed for the capture of exosomes.

Exosomes are nanoparticles shed from most cells in the human body and are found in the blood stream. Exosomes have been the focus of intense and growing research in recent years. They contain a unique molecular cargo of nucleic acids, proteins and lipids that are important for cellular communication and have cell-source dependent bioactive effects such as angiogenesis, inflammation, fibrosis, and tissue regeneration. As a result, they are recognised as having important roles in human diagnostics and therapeutics.

BARD1 CEO Dr Leeorne Hinch said: "This patent family provides intellectual property protection for our game-changing Molecular Net biomarker capture technology in the world's largest market, the USA. Our first product under this technology is EXO-NET™, that has been specially designed to capture exosomes from body fluids and cell culture for diagnostic and therapeutic purposes. BARD1 plans to launch a Research Use Only (RUO) version of EXO-NET™ for sale to researchers, diagnostic companies and biopharmaceutical companies in the USA in 2021."

Marketing and sales of RUO EXO-NET as a research tool has the potential to embed EXO-NETs and other Molecular Net products into the discovery, research and development phases for multiple liquid biopsy and therapeutic applications, as well as generate multiple new publications. Importantly, this may lead to future licensing agreements for development and commercialisation of exosome-based products incorporating the Molecular Net technology.

BARD1's EXO-NET product pipeline includes specific EXO-NETs custom-designed to capture a variety of exosomes for both diagnostic and therapeutic purposes. Dr Peter French, BARD1 Chief Scientific Officer, said: "Exosomes are increasingly being recognised as vital for cellular communication and can be both biomarkers of disease and a potential new therapeutic modality. In fact, they have been proposed as having similar potential to cell therapies for impact on human health. Research into exosomes is growing significantly but until now commercialisation of exosome-based products has been limited by numerous challenges in isolating them. BARD1 believes that EXO-NET™ overcomes these challenges and is demonstrating the value of the technology through several early-stage research collaborations with the University of Sydney, University of Queensland, Minomic and VivaZome Therapeutics. These collaborations cover initial evaluation of the EXO-NET™ product, and potential development of exosome-based diagnostics and therapeutics."

It is important to note that there is much more to the Molecular Net technology than EXO-NET. The Molecular Net technology is a flexible, scalable biomarker capture platform with the potential to

revolutionise liquid biopsy preparation. It is an advanced capture technology based on affinity capture and size exclusion for rapid isolation of biomarkers, including cells, proteins, nucleic acids, viruses and bacteria, and exosomes, in a rapid, specific and scalable manner for both diagnostic and therapeutic applications.

Dr Emily Stein PhD, inventor and BARD1 R&D Manager (NET technology) said: "I invented the Molecular Net technology to fill an unmet need in the market for better capture technologies to enable highly sensitive and specific diagnosis of life-threatening diseases including cancer. Granting of this US patent validates the novelty of the technology that we have shown can capture exosomes for potential diagnostic and therapeutic applications that can lead to better exosome-based products to help save patients' lives."

There is a clear market need for efficient exosome isolation technologies. The global exosome market is expected to reach US\$2.3b by 2030, growing at 18.8% CAGR.¹ The Company is in early discussions with leading multinationals to manufacture and distribute its RUO EXO-NET™ product in the USA and other countries.

Authorised by the Company Secretary, Tony Di Pietro.

- ENDS -

COMPANY CONTACTS

Dr Leearne Hinch

CEO

E leearne@bard1.com

M +61 400 414 416

Dr Geoff Cumming

Non-executive Chairman

E geoff.cumming@bard1.com

M +61 417 203 021

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) (**BARD1** or the **Company**) is a leading Australian diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising best-in-class diagnostic solutions for healthcare professionals and patients. The cancer diagnostics portfolio includes the commercialised hTERT test used as an adjunct to urine cytology testing and diagnostic tests in development for ovarian, breast, lung, prostate and pancreatic cancers. For more information on BARD1, see www.bard1.com.

FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.

¹ Grand View Research, 2018